Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on VolitionRX (AMEX:VNRX) and maintained a price target of $2.5.
May 16, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Ross Osborn has reiterated an Overweight rating on VolitionRX and maintained a price target of $2.5.
The reiteration of an Overweight rating and the maintenance of a $2.5 price target by a reputable analyst can boost investor confidence in VolitionRX, potentially leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100